Clinical Trial

Assessment of Serum Catestatin Level in Acne Vulgaris Patients

Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated July 8, 2025 (before its estimated January 1, 2026 completion). Its status may not reflect the trial's current state.
Summary
Acne vulgaris is a persistent inflammatory condition of the pilosebaceous unit, affecting 85% of people between the ages of 12 and 24, it is regarded as one of the most common diseases in teenagers and young adults. Catestatin, a peptide derived from chromogranin A (CgA), was first discovered in 1997 as an acute nicotinic-cholinergic antagonist. Later, it was determined that CST is a pleiotropic hormone.
Trial Details
NCT Number NCT07054398
Lead Sponsor Aswan University
Conditions Acne Vulgaris
Enrollment 60 participants
Start Date 2025-01-10
Primary Completion 2026-01-01 (estimated)
Study Completion 2026-01-10 (estimated)
Updated on ClinicalTrials.gov 2025-07-08